Fig. 9
From: The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer
Cav3.2 expression stratifies the survival of breast cancer patients. The survival of patients from both the METABRIC and Kaplan–Meier Plotter cohorts were stratified based on the expression of Cav3.2 for each of the clinical subgroups and within those groups, in patients treated with chemotherapy (CT). METABRIC patients were stratified on overall survival (OS) and the KM-Plotter cohort on relapse free survival (RFS). Log-rank hazard ratios (HR) and corresponding P values are shown (a). Kaplan–Meier curves from data shown in panel A for ER+ patients (b i, ii) and those with HER2-positive tumours (HER+) treated with CT (b iii, iv). Tumours were stratified on the basis of their CACNA1H expression into low and high expressing groups, numbers indicated in brackets